JP2005027667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005027667A5 JP2005027667A5 JP2004186386A JP2004186386A JP2005027667A5 JP 2005027667 A5 JP2005027667 A5 JP 2005027667A5 JP 2004186386 A JP2004186386 A JP 2004186386A JP 2004186386 A JP2004186386 A JP 2004186386A JP 2005027667 A5 JP2005027667 A5 JP 2005027667A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- antibody
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims 43
- 210000004027 cell Anatomy 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 21
- 125000003729 nucleotide group Chemical group 0.000 claims 21
- 208000037841 lung tumor Diseases 0.000 claims 12
- 210000004881 tumor cell Anatomy 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 210000004072 lung Anatomy 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 9
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 8
- 230000014509 gene expression Effects 0.000 claims 7
- 208000020816 lung neoplasm Diseases 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 208000013718 rectal benign neoplasm Diseases 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000004565 tumor cell growth Effects 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13838599P | 1999-06-09 | 1999-06-09 | |
| US14479099P | 1999-07-20 | 1999-07-20 | |
| US14684399P | 1999-08-03 | 1999-08-03 | |
| US14818899P | 1999-08-10 | 1999-08-10 | |
| US14932099P | 1999-08-17 | 1999-08-17 | |
| US14932799P | 1999-08-17 | 1999-08-17 | |
| US14939699P | 1999-08-17 | 1999-08-17 | |
| US15011499P | 1999-08-20 | 1999-08-20 | |
| US15173499P | 1999-08-31 | 1999-08-31 | |
| US15170099P | 1999-08-31 | 1999-08-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001502580A Division JP2003501087A (ja) | 1999-06-09 | 2000-05-15 | 腫瘍の治療のための組成物と方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005181558A Division JP2006006331A (ja) | 1999-06-09 | 2005-06-22 | 腫瘍の治療のための組成物と方法 |
| JP2005181588A Division JP2006006332A (ja) | 1999-06-09 | 2005-06-22 | 腫瘍の治療のための組成物と方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005027667A JP2005027667A (ja) | 2005-02-03 |
| JP2005027667A5 true JP2005027667A5 (enExample) | 2005-09-22 |
| JP4252501B2 JP4252501B2 (ja) | 2009-04-08 |
Family
ID=27581055
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001502580A Pending JP2003501087A (ja) | 1999-06-09 | 2000-05-15 | 腫瘍の治療のための組成物と方法 |
| JP2004186386A Expired - Fee Related JP4252501B2 (ja) | 1999-06-09 | 2004-06-24 | 腫瘍の治療のための組成物と方法 |
| JP2005181534A Expired - Lifetime JP4260778B2 (ja) | 1999-06-09 | 2005-06-22 | 腫瘍の治療のための組成物と方法 |
| JP2005181558A Pending JP2006006331A (ja) | 1999-06-09 | 2005-06-22 | 腫瘍の治療のための組成物と方法 |
| JP2005181588A Pending JP2006006332A (ja) | 1999-06-09 | 2005-06-22 | 腫瘍の治療のための組成物と方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001502580A Pending JP2003501087A (ja) | 1999-06-09 | 2000-05-15 | 腫瘍の治療のための組成物と方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005181534A Expired - Lifetime JP4260778B2 (ja) | 1999-06-09 | 2005-06-22 | 腫瘍の治療のための組成物と方法 |
| JP2005181558A Pending JP2006006331A (ja) | 1999-06-09 | 2005-06-22 | 腫瘍の治療のための組成物と方法 |
| JP2005181588A Pending JP2006006332A (ja) | 1999-06-09 | 2005-06-22 | 腫瘍の治療のための組成物と方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP1657256B1 (enExample) |
| JP (5) | JP2003501087A (enExample) |
| AT (2) | ATE440109T1 (enExample) |
| AU (1) | AU4851900A (enExample) |
| CA (1) | CA2371434A1 (enExample) |
| DE (2) | DE60042799D1 (enExample) |
| ES (2) | ES2331657T3 (enExample) |
| WO (1) | WO2000075317A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| DE69942782D1 (de) | 1998-11-27 | 2010-10-28 | Ucb Sa | Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung |
| US6960651B2 (en) | 1999-06-29 | 2005-11-01 | Millennium Pharmaceuticals, Inc. | TANGO 332 polypeptides |
| EP1194534A4 (en) * | 1999-06-29 | 2004-03-24 | Millennium Pharm Inc | NOVEL GENES ENCODING PROTEINS THAT CAN BE USED IN DIAGNOSTIC, PREVENTIVE, THERAPEUTIC OR OTHER AREAS |
| JP2003513668A (ja) * | 1999-11-12 | 2003-04-15 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 6個のヒト分泌タンパク質 |
| WO2001047957A2 (en) * | 1999-12-29 | 2001-07-05 | Zymogenetics, Inc. | Human fgf-10- (kgf-2)-like protein zfgf-10 |
| AU5056501A (en) * | 2000-03-31 | 2001-10-08 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
| JP2004520005A (ja) * | 2000-06-19 | 2004-07-08 | エフ.ホフマン−ラ ロシュ アーゲー | オステオレビン遺伝子多型性 |
| US7332276B2 (en) * | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| EP1636270B1 (en) | 2003-06-16 | 2016-07-20 | UCB Pharma S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
| JP2014511842A (ja) | 2011-03-25 | 2014-05-19 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体結晶およびその製剤 |
| DK2739311T3 (en) | 2011-08-04 | 2018-04-23 | Amgen Inc | Method of treating bone slit defects |
| EA036740B1 (ru) | 2011-12-28 | 2020-12-15 | Эмджен Инк. | Способ увеличения высоты альвеолярного отростка посредством применения антител к склеростину |
| WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN119241705A (zh) | 2018-03-30 | 2025-01-03 | 安姆根有限公司 | C末端抗体变体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| JP3399948B2 (ja) * | 1992-06-26 | 2003-04-28 | ザ トラスティーズ オブ プリンストン ユニバーシティ | P90抗体またはプローブを用いた前癌細胞または癌細胞の検出方法 |
| WO1995026201A1 (en) * | 1994-03-28 | 1995-10-05 | La Jolla Cancer Research Foundation | Brevican, a glial cell proteoglycan |
| US5635370A (en) * | 1994-04-08 | 1997-06-03 | Yale University | DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides |
| WO1999014327A2 (en) * | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer |
| WO1998031799A2 (en) * | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | Polynucleotides and polypeptides encoding receptors |
| KR100506786B1 (ko) * | 1997-11-25 | 2005-08-08 | 제넨테크, 인크. | 섬유아세포 성장인자-19 |
| AU766787B2 (en) * | 1998-01-23 | 2003-10-23 | Beth Israel Deaconess Medical Center | Meth1 and meth2 polynucleotides and polypeptides |
| EP1194534A4 (en) * | 1999-06-29 | 2004-03-24 | Millennium Pharm Inc | NOVEL GENES ENCODING PROTEINS THAT CAN BE USED IN DIAGNOSTIC, PREVENTIVE, THERAPEUTIC OR OTHER AREAS |
-
2000
- 2000-05-15 EP EP05024729A patent/EP1657256B1/en not_active Expired - Lifetime
- 2000-05-15 JP JP2001502580A patent/JP2003501087A/ja active Pending
- 2000-05-15 ES ES06001196T patent/ES2331657T3/es not_active Expired - Lifetime
- 2000-05-15 DE DE60042799T patent/DE60042799D1/de not_active Expired - Lifetime
- 2000-05-15 EP EP06001196A patent/EP1683811B1/en not_active Expired - Lifetime
- 2000-05-15 EP EP00930756A patent/EP1185642A2/en not_active Withdrawn
- 2000-05-15 DE DE60043125T patent/DE60043125D1/de not_active Expired - Lifetime
- 2000-05-15 AT AT06001196T patent/ATE440109T1/de not_active IP Right Cessation
- 2000-05-15 CA CA002371434A patent/CA2371434A1/en not_active Abandoned
- 2000-05-15 AU AU48519/00A patent/AU4851900A/en not_active Abandoned
- 2000-05-15 WO PCT/US2000/013358 patent/WO2000075317A2/en not_active Ceased
- 2000-05-15 AT AT05024729T patent/ATE444971T1/de not_active IP Right Cessation
- 2000-05-15 ES ES05024729T patent/ES2332916T3/es not_active Expired - Lifetime
-
2004
- 2004-06-24 JP JP2004186386A patent/JP4252501B2/ja not_active Expired - Fee Related
-
2005
- 2005-06-22 JP JP2005181534A patent/JP4260778B2/ja not_active Expired - Lifetime
- 2005-06-22 JP JP2005181558A patent/JP2006006331A/ja active Pending
- 2005-06-22 JP JP2005181588A patent/JP2006006332A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005027667A5 (enExample) | ||
| CA2479494A1 (en) | Compositions and methods associated with pro5725 and its use for the diagnosis of lung and colon tumor | |
| US7198899B2 (en) | Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers | |
| JP2006081548A5 (enExample) | ||
| JP2008301822A5 (enExample) | ||
| JP2005522986A5 (enExample) | ||
| CA2679954A1 (en) | Assessment of risk for colorectal cancer | |
| JP2009519002A5 (enExample) | ||
| JP2005046146A5 (enExample) | ||
| KR20060125923A (ko) | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 | |
| JP2009001563A5 (enExample) | ||
| WO1999033963A1 (en) | Metastatic cancer regulated gene | |
| JP2005535601A5 (ja) | 可溶型の炭酸脱水酵素IX(s-CA IX)、s-CA IXを検出するためのアッセイ、CA IXとHER-2/neu/c-erbB-2の同時発現、非免疫優性エピトープに対するCA IX特異的モノクローナル抗体 | |
| AU2007319360A1 (en) | Methods of treating, diagnosing or detecting cancer | |
| CN107001480B (zh) | 用于人c-maf的结合成员 | |
| JP2009039107A5 (enExample) | ||
| JP2021046417A (ja) | 抗Aggrusモノクローナル抗体、CLEC−2との結合に必要なAggrusの領域、及びAggrus−CLEC‐2結合阻害剤のスクリーニング方法 | |
| US20050170500A1 (en) | Methods for identifying risk of melanoma and treatments thereof | |
| JP2004138610A5 (enExample) | ||
| JP2004513614A5 (enExample) | ||
| US8962808B2 (en) | EGFR-related polypeptides and methods of use | |
| US20050277118A1 (en) | Methods for identifying subjects at risk of melanoma and treatments thereof | |
| TW202535930A (zh) | 同功型選擇性抗-TGF-β 抗體及其使用方法 | |
| JP2007508020A5 (enExample) | ||
| JP2004515215A5 (enExample) |